Industry
Drug Manufacturers - General
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Loading...
Open
106.61
Mkt cap
208B
Volume
1.1M
High
106.69
P/E Ratio
18.58
52-wk high
120.92
Low
106.13
Div yield
0.07
52-wk low
92.35
Portfolio Pulse from Benzinga Newsdesk
September 17, 2024 | 5:05 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 8:33 am
Portfolio Pulse from Avi Kapoor
September 11, 2024 | 1:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 11:43 am
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 10:29 am
Portfolio Pulse from Vandana Singh
September 09, 2024 | 6:05 pm
Portfolio Pulse from Vandana Singh
September 05, 2024 | 6:34 pm
Portfolio Pulse from Avi Kapoor
September 05, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 12:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.